Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.62 |
| ▸ | SELL | P14151 | 1/20 | 0.62 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.58 |
| ▸ | MAG | P20916 | 7/20 | 0.58 |
| ▸ | SELE | P16581 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28100889 | 0.95 | MAG (0.59) | SELPSELLSIGLEC7MAGSELE | |
| SCHEMBL23857822 | 0.92 | MAG (0.62) | SELPSELLSIGLEC7MAGSELE | |
| SCHEMBL29361397 | 0.92 | MAG (0.62) | SELPSELLSIGLEC7MAGSELE | |
| SCHEMBL29358356 | 0.92 | MAG (0.64) | SELPSELLSIGLEC7MAGSELE | |
| SCHEMBL30830404 | 0.91 | SELP (0.56) | SELPSELLSIGLEC7MAGSELE | |
| SCHEMBL29709547 | 0.91 | SELP (0.63) | SELPSELLSIGLEC7MAGSELE | |
| SCHEMBL31700532 | 0.91 | SELP (0.68) | SELPSELLSIGLEC7MAGSELE | |
| SCHEMBL29449201 | 0.90 | SIGLEC7 (0.66) | SELPSELLSIGLEC7MAGSELE | |
| SCHEMBL29395515 | 0.89 | MAG (0.61) | SELPSELLSIGLEC7MAGSELE | |
| SCHEMBL21570085 | 0.89 | SIGLEC7 (0.62) | SELPSELLSIGLEC7MAGSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702138-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | Inbiose N.V. (BE) | 2026-03-04 | — | — | EP | claimed |
| EP-4630541-A1 | GENETICALLY MODIFIED UDP-N-ACETYLGLUCOSAMINE PRODUCING CELLS | DSM IP Assets B.V. (NL) | 2025-10-15 | — | — | EP | claimed |
| EP-4623089-A1 | TWO-STRAIN SYSTEM FOR PRODUCING OLIGOSACCHARIDES | DSM IP Assets B.V. (NL) | 2025-10-01 | — | — | EP | claimed |
| WO-2024130119-A9 | SYNBIOTIC COMPOSITIONS FOR SHORT CHAIN FATTY ACID PRODUCTION | PROLACTA BIOSCIENCE, INC. (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2024223815-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | INBIOSE N.V. (BE) | 2024-10-31 | — | — | WO | claimed |
| WO-2024130119-A2 | SYNBIOTIC COMPOSITIONS FOR SHORT CHAIN FATTY ACID PRODUCTION | PROLACTA BIOSCIENCE, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024121399-A1 | GENETICALLY MODIFIED UDP-N-ACETYLGLUCOSAMINE PRODUCING CELLS | DSM IP ASSETS B.V. (NL) | 2024-06-13 | — | — | WO | claimed |
| WO-2024110667-A1 | TWO-STRAIN SYSTEM FOR PRODUCING OLIGOSACCHARIDES | DSM IP ASSETS B.V. (NL) | 2024-05-30 | — | — | WO | claimed |
| CN-114594169-A | Quantitative detection method for oligosaccharide content in breast milk | 中国科学院大连化学物理研究所 | 2022-06-07 | — | — | CN | claimed |
| EP-4731778-A2 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260069626-A1 | Compositions and Methods to Protect and Enhance Structural and Functional Integrity of the Intestinal Glycocalyx | CALROY HEALTH SCIENCES, LLC | 2026-03-12 | — | — | US | disclosed |
| US-20260062726-A1 | HYBRID METHOD FOR PRODUCING COMPLEX HMOS | DSM IP ASSETS BV (NL) | 2026-03-05 | — | — | US | disclosed |
| EP-4702138-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | Inbiose N.V. (BE) | 2026-03-04 | — | — | EP | disclosed |
| EP-4662305-A1 | PRODUCTION OF A DISACCHARIDE AND/OR MILK OLIGOSACCHARIDE BY A CELL WITH REDUCED SYNTHESIS OF UDP-GLCNAC | Inbiose N.V. (BE) | 2025-12-17 | — | — | EP | disclosed |
| WO-2022155201-A1 | SYNBIOTIC TREATMENT REGIMENS | PROLACTA BIOSCIENCE, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022129470-A1 | VARIANT SUCROSE PERMEASE POLYPEPTIDES | INBIOSE N.V. (BE) | 2022-06-23 | — | — | WO | disclosed |
| EP-4003061-A1 | NUTRITIONAL COMPOSITION COMPRISING MILK FAT AND IMMUNOGLOBULIN | FrieslandCampina Nederland B.V. (NL) | 2022-06-01 | — | — | EP | disclosed |
| US-11324765-B2 | Inhibiting inflammation with milk oligosaccharides | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220133758-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3980542-A1 | OPTIMAL CHROMOSOMAL INSERTION LOCI | Inbiose N.V. (BE) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324765-B2 | Inhibiting inflammation with milk oligosaccharides | FUT5, FUT6, ST3GAL3 | SELP 109/4885SELL 132/4885SIGLEC7 10/4885 |
| US-20260069626-A1 | Compositions and Methods to Protect and Enhance Structural and Functional Integrity of the Intestinal Glycocalyx | SI, FUT5, FABP2 | SELP 252/4885SELL 316/4885SIGLEC7 58/4885 |
| US-20260062726-A1 | HYBRID METHOD FOR PRODUCING COMPLEX HMOS | FUCA1, GMDS, MANBA | SELP 2667/4885SELL 2472/4885SIGLEC7 474/4885 |
| US-20220133758-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS | FUT6, FUCA2, FUCA1 | SELP 412/4885SELL 311/4885SIGLEC7 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.